Preprint Review Version 1 This version is not peer-reviewed

HDAC6 – An Emerging Target against Chronic Myeloid Leukemia?

Version 1 : Received: 3 January 2020 / Approved: 4 January 2020 / Online: 4 January 2020 (06:18:22 CET)

A peer-reviewed article of this Preprint also exists.

Losson, H.; Schnekenburger, M.; Dicato, M.; Diederich, M. HDAC6—an Emerging Target Against Chronic Myeloid Leukemia? Cancers 2020, 12, 318. Losson, H.; Schnekenburger, M.; Dicato, M.; Diederich, M. HDAC6—an Emerging Target Against Chronic Myeloid Leukemia? Cancers 2020, 12, 318.

Journal reference: Cancers 2020, 12, 318
DOI: 10.3390/cancers12020318

Abstract

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Subject Areas

histone deacetylase 6 inhibitor; personalized treatment; heat shock protein 90α; leukemia stem cells; imatinib resistance; targeted therapy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.